Briefing
Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma.
ASCO 2024 methods abstract (Seo first, Tang last): in 5 oligometastatic ccRCC patients, baseline MRD calls from Myriad High-Definition MRD sub-panels designed from primary-tumor vs metastatic subsites were fully concordant in 3 of 5 patients, at tumor fractions from 0.0004% to 0.027%.
- n: 5 patients; 13 primary-tumor, 24 metastatic-lesion, and matched buffy-coat samples; baseline plasma before radiotherapy
- Assay: Myriad Genetics High-Definition MRD assay: tumor/normal WGS (median coverage 30x); a sub-panel of up to 1,000 somatic variants designed for each lesion subsite; hybridization capture from plasma cfDNA